Amendment to the Claims:

Claims 1-7 (Withdrawn)

8. (Currently Amended) A transgenic mouse whose genome comprises a homozygous disruption in the Cer1 gene, said gene comprising the~~a~~ nucleotide sequence of~~set forth in~~ SEQ ID NO: 1, ~~wherein the disruption comprises a disruption of the nucleotide sequence set forth in SEQ ID NO: 1, and~~ wherein said transgenic mouse exhibits, relative to a wild-type mouse, ~~a phenotype selected from the group consisting of a~~ increased anxiety~~decrease in average velocity of movement during open field testing, a decrease in total distance traveled during open field testing, an increase in the number of fecal boli during open field testing, and a decrease in total time immobile during the tail suspension test~~.

Claim 9 (Withdrawn)

10. (Currently Amended) A method of producing the~~a~~ transgenic mouse of claim 8~~comprising a homozygous disruption in a cerberus gene set forth in SEQ ID NO: 1~~, the method comprising:

(a) introducing a construct that targets the nucleotide sequence set forth in SEQ ID NO: 1 into a mouse embryonic stem cell;

(b) introducing the embryonic stem cell into a blastocyst;

(c) implanting the resulting blastocyst into a pseudopregnant mouse, wherein said pseudopregnant mouse gives birth to a chimeric mouse; and

(d) breeding the chimeric mouse to produce ~~the~~ said transgenic ~~mouse comprising a disruption in the cerberus gene, wherein the transgenic mouse when homozygous for the disruption exhibits, relative to a wild-type mouse, a phenotype selected from the group consisting of a decrease in average velocity of movement during open field testing, a decrease in total distance traveled during open field testing, an increase in the number of fecal boli during open field testing, and a decrease in total time immobile during the tail suspension test~~.

Claims 11-16 (Withdrawn)

17. (New). The transgenic mouse of claim 1 further exhibiting anti-depressive behavior and/or hypoactivity.